This article has been updated from a previous version to include comments made by Qiagen executives during its earnings call.

NEW YORK (GenomeWeb) – Qiagen reported after the close of the market Monday that its third quarter revenues grew 7 percent year over year on both a reported basis and at constant exchange rates (CER).

For the three months ended Sept. 30, Qiagen reported revenues of $364.0 million, up from $338.7 million a year ago and just beating the average analyst estimate of $363.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.